Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.56 |
| ▸ | RAB9A | P51151 | 12/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.53 |
| ▸ | RELA | Q04206 | 4/20 | 0.53 |
| ▸ | SCD | O00767 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24706386 | 0.87 | MAPT (0.56) | NPC1RAB9ASMN1; SMN2HTTCYP3A4 | |
| SCHEMBL24705956 | 0.84 | DYRK1A (0.58) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL24707371 | 0.84 | MAPT (0.51) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL24705959 | 0.83 | DYRK1A (0.53) | NPC1RAB9ASMN1; SMN2HTTDYRK1A | |
| SCHEMBL24707000 | 0.81 | MAPT (0.55) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL24706384 | 0.81 | RAB9A (0.52) | NPC1RAB9AHTTCYP1A2CYP3A4 | |
| SCHEMBL24707315 | 0.81 | SMN1; SMN2 (0.55) | NPC1RAB9ASMN1; SMN2HTTCYP3A4 | |
| SCHEMBL10991640 | 0.79 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL21652289 | 0.78 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 | |
| SCHEMBL24706983 | 0.78 | GAA (0.44) | NPC1RAB9ASMN1; SMN2HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223932-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| EP-1223932-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001024796-A1 | 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-12 | — | — | WO | claimed |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-15 | — | — | US | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1276723-A2 | PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY | Kinetek Pharmaceuticals, Inc. (CA) | 2003-01-22 | — | — | EP | disclosed |
| US-6436915-B1 | ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS | KINETEK PHARMACEUTICALS, INC. (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020042501-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001077080-A2 | PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY | KINETEK PHARMACEUTICALS, INC. (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | NPC1 2611/4885RAB9A 4545/4885SMN1; SMN2 4161/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | NPC1 2611/4885RAB9A 4545/4885SMN1; SMN2 4161/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | NPC1 3205/4885RAB9A 3555/4885SMN1; SMN2 2243/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | NPC1 2227/4885RAB9A 4226/4885SMN1; SMN2 3557/4885 |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | AANAT, NAT1, HNMT | NPC1 3755/4885RAB9A 2732/4885SMN1; SMN2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.